Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$4.53 – $10.65
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M | $14.5M | $12.4M | $27.9M | $209.7M | $222.0M | $980.6M | $559.3M |
| Cost of revenue | $0 | $2.1M | $2.0M | $3.3M | $22.0M | $30.5M | $29.1M | $131.9M |
| Gross profit | $6.8M | $12.4M | $10.5M | $24.6M | $187.7M | $191.4M | $951.6M | $427.4M |
| Gross margin | 100.0% | 85.6% | 84.2% | 88.1% | 89.5% | 86.2% | 97.0% | 76.4% |
| R&D | $249.6M | $463.9M | $564.6M | $766.5M | $743.1M | $707.0M | $947.2M | $1.08B |
| Operating income | −$342.5M | −$613.1M | −$684.4M | −$933.2M | −$883.4M | −$872.6M | −$369.7M | −$1.18B |
| EBITDA | −$324.1M | −$1.45B | −$641.8M | −$916.0M | −$836.0M | −$743.6M | −$237.6M | −$1.10B |
| Net income | −$345.3M | −$1.48B | −$677.6M | −$782.4M | −$882.9M | −$925.6M | −$405.4M | −$1.21B |
| Net margin | -5072.8% | -10202.7% | -5442.6% | -2803.4% | -421.0% | -417.0% | -41.3% | -216.5% |
| EPS (diluted) | -1.67 | -12.69 | -3.14 | -3.07 | -3.35 | -3.28 | -1.37 | -3.43 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $942M | $-1.46 | $-2.99–$-0.73 | 1 |
| 2027 | $1.6B | $-0.75 | $-1.54–$-0.38 | 1 |
| 2028 | $2.4B | $-0.40 | $-0.82–$-0.20 | 1 |
| 2029 | $3.0B | $-1.06 | $-2.18–$-0.53 | 1 |
Forward consensus · source: Financial Modeling Prep
ASCENTAGE PHARMA GROUP
No one on the platform currently holds ASPHF.
No tracked institution reports a position in ASPHF as of their last filing.
No one on the platform has traded ASPHF yet.
| +0.00% |
| $1.6B |
| — |
| GALNFGalenica AG | $115.00 | +0.00% | $5.7B | — |
| INVVYIndivior PLC | $21.85 | +0.00% | $3.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 2.8× sales vs its 4.2× historical median P/S.
Fair value ≈ $6.81 · price $4.53 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.